Skin disorder caused by infection
MONDO:0024294Skin diseases caused by bacteria, fungi, parasites, or viruses.
Also known as: disease, infectious skin, diseases, infectious skin, infectious skin disease, infectious skin diseases, skin disease, infectious
350 clinical trials for this condition and its sub-types, 3 tagged with Skin disorder caused by infection itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Skin disorder caused by infection
-
Skin infection 12 trials · 152 incl. sub-types
14 sub-types
- Tinea infection 1 trial · 116 incl. sub-types Sub-types →
- Scabies 12 trials Sub-types →
- Demodex folliculitis 5 trials
- Impetigo 5 trials Sub-types →
- Infection by Trypanosoma gambiense 3 trials
- Erysipelas 1 trial
- Pthirus pubis infestation 0 trials
- Cercarial dermatitis 0 trials
- Cutaneous diphtheria 0 trials
- Furunculosis 0 trials
- Gonococcal keratitis 0 trials
- Herpes simplex dermatitis 0 trials
- Herpes zoster dermatitis 0 trials Sub-types →
- Sycosis barbae 0 trials
-
Herpes zoster 73 trials
3 sub-types
- Geniculate herpes zoster 0 trials
- Ophthalmic herpes zoster 0 trials
- Zoster sine herpete 0 trials
-
Skin disease caused by bacterial infection 13 trials · 57 incl. sub-types
17 sub-types
- Cellulitis 29 trials · 31 incl. sub-types Sub-types →
- Hordeolum 1 trial · 7 incl. sub-types Sub-types →
- Impetigo 5 trials Sub-types →
- Cutaneous anthrax 2 trials
- Erysipelas 1 trial
- Pinta disease 1 trial
- Aquarium granuloma 0 trials
- Bacillary angiomatosis 0 trials
- Bacterial exanthem 0 trials
- Bullous impetigo 0 trials
- Cutaneous diphtheria 0 trials
- Cutaneous syphilis 0 trials Sub-types →
- Cutaneous tuberculosis 0 trials Sub-types →
- Gas gangrene 0 trials
- Gonococcal keratitis 0 trials
- Staphylococcal scalded skin syndrome 0 trials
- Sycosis barbae 0 trials
-
Parasitic skin disorder 1 trial · 37 incl. sub-types
6 sub-types
- Parasitic ectoparasitic infectious disease 0 trials · 16 incl. sub-types Sub-types →
- Cutaneous leishmaniasis 14 trials Sub-types →
- Demodex folliculitis 5 trials
- Infection by Trypanosoma gambiense 3 trials
- Cercarial dermatitis 0 trials
- Demodicidosis of sebaceous gland 0 trials
-
Chickenpox 26 trials
-
Common wart 26 trials
-
Plantar wart 10 trials
-
Hand, foot and mouth disease 7 trials
-
Viral exanthem 0 trials · 3 incl. sub-types
1 sub-type
- Erythema infectiosum 3 trials
-
Epstein-Barr virus hepatitis 0 trials
-
Exanthema subitum 0 trials
-
Herpetic whitlow 0 trials
-
Variola major infectious disease 0 trials
Most studied deeper sub-types
-
Rewriting the code: a One-Time gene fix for a rare immune disease?
Cure By invitation onlyThis trial tests a one-time gene therapy for WHIM syndrome, a rare inherited immune disorder that causes severe infections. Doctors collect a person's own blood stem cells, use base editing to correct the faulty CXCR4 gene, and return the edited cells to the body. The goal is to …
Phase 1/2 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Cure
Last updated Sep 21, 2026 21:00 UTC
-
New shingles vaccine trial aims for safer protection in adults 40+
Vaccine By invitation onlyThis early-stage trial tests a new shingles vaccine in 120 adults aged 40 and older. The main goal is to check safety and side effects at different doses, while also looking at how well the vaccine triggers an immune response. Participants receive either the vaccine or a placebo,…
Phase 1 • Sponsor: Changchun BCHT Biotechnology Co. • Aim: Vaccine
Last updated Jun 27, 2026 13:05 UTC
-
New shingles vaccine Z-1018 takes on shingrix in Head-to-Head trial
Vaccine OngoingThis study tests a new shingles vaccine called Z-1018 in about 764 healthy adults aged 50 and older. It compares Z-1018 to the current vaccine, Shingrix, to see if it is safe and triggers a strong immune response. The trial is in early phases (1 and 2), so the main focus is on sa…
Phase 1/2 • Sponsor: Dynavax Technologies Corporation • Aim: Vaccine
Last updated Jun 27, 2026 13:00 UTC
-
MRNA vaccine takes on shingles: could it beat shingrix?
Vaccine OngoingThis early-stage trial is testing a new mRNA vaccine called ABO1108 to prevent shingles in adults aged 40 and above. Around 180 healthy volunteers will receive two shots of either the new vaccine at different doses, a placebo, or the existing Shingrix vaccine. The main goal is to…
Phase 1 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:32 UTC
-
New mRNA shingles vaccine shows promise in Mid-Stage trial
Vaccine OngoingThis study tests a new mRNA vaccine called ABO1108 to see if it can prevent shingles in adults aged 40 and above. About 300 healthy volunteers will receive two shots, two months apart, and be compared to a placebo group. The goal is to measure the immune response and check for sa…
Phase 2 • Sponsor: Suzhou Abogen Biosciences Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 12:31 UTC
-
Can an EV71 vaccine protect older kids too?
Vaccine OngoingThis study tests an inactivated EV71 vaccine (Envacgen®) in healthy children aged 6 to under 10 years and compares their immune response and safety to children aged 2 to under 6 years. Around 378 children will receive two shots 57 days apart. The goal is to see if the vaccine wor…
Phase 3 • Sponsor: Medigen Vaccine Biologics Corp. • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
-
New shingles vaccine shows promise in Head-to-Head trial
Vaccine OngoingThis study tests a new shingles vaccine called JCXH-105 in healthy adults aged 50 and older. It compares the new vaccine to the current standard, Shingrix, to see if it is safe and triggers a strong immune response. About 467 participants will receive either JCXH-105 or Shingrix,…
Phase 2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New shingles vaccine trial aims to protect millions over 40
Vaccine OngoingThis study tests a new shingles vaccine in 960 healthy adults aged 40 and older. The goal is to see if it is safe and triggers a strong immune response. Researchers will monitor side effects and measure antibody levels over time. This is an early-stage trial to help develop a bet…
Phase 1/2 • Sponsor: Ab&B Bio-tech Co., Ltd.JS • Aim: Vaccine
Last updated Jun 27, 2026 12:01 UTC
-
Could this new vaccine stop shingles for years?
Vaccine OngoingThis Phase 3 trial is testing a new shingles vaccine in 12,000 adults aged 40 and older. The goal is to see if the vaccine can prevent shingles for up to 3 years after the two-dose series. Participants previously received the vaccine or a placebo, and researchers are tracking who…
Phase 3 • Sponsor: MAXVAX Biotechnology Limited Liability Company • Aim: Vaccine
Last updated Jun 27, 2026 11:00 UTC
-
New vaccine could stop recurring yeast infections in their tracks
Vaccine OngoingThis study tests a new vaccine called Candi5V in 251 women who get frequent yeast infections (at least 3 per year). The vaccine is designed to train the body's immune system to fight Candida fungus. Researchers will check if it's safe and if it reduces future infections.
Phase 1/2 • Sponsor: LimmaTech Biologics AG • Aim: Vaccine
Last updated Jun 27, 2026 09:10 UTC
-
New shingles vaccine candidate enters Mid-Stage trial
Vaccine OngoingThis study tests a new shingles vaccine called LYB004 in 840 adults aged 40 and older in China. Participants receive one of four different doses of the vaccine or a placebo. The goal is to see how well the vaccine triggers an immune response and whether it is safe.
Phase 2 • Sponsor: Guangzhou Patronus Biotech Co., Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:07 UTC
-
New shingles vaccine CRV-101 takes on shingrix in Head-to-Head trial
Vaccine OngoingThis phase 2 study tests a new shingles vaccine called CRV-101 (amezosvatein) against the current standard, Shingrix, in about 1,500 adults aged 50 and older. The goal is to see if CRV-101 is safer and triggers a strong immune response. Participants receive two shots and are moni…
Phase 2 • Sponsor: Curevo Inc • Aim: Vaccine
Last updated Jun 27, 2026 07:53 UTC
-
Can a cancer vaccine injections clear warts that Won't go away?
Disease control OngoingThis phase 2 trial tests whether Gardasil-9, a vaccine normally used to prevent HPV infection, can treat warts that have not responded to standard treatments. Researchers inject the vaccine directly into the wart, rather than into a muscle, and compare its effect against a placeb…
Phase 2 • Sponsor: Rush University Medical Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a parasite drug clear flat warts? new trial investigates
Disease control OngoingThis trial tests whether ivermectin, a drug used for parasitic infections, can treat flat warts (plane warts). Researchers will give some participants ivermectin (by mouth and on the skin) and others a placebo to see if the drug helps clear the warts. The study includes people of…
Phase 2 • Sponsor: Al-Azhar University • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Brain-Body training may give taekwondo athletes an edge
Disease control OngoingThis study tests whether adding neuro-athletic training—exercises that challenge the nervous system with extra sensory input—to regular taekwondo practice can improve balance, agility, and jumping ability while reducing injury risk. Researchers will compare two groups of 13 athle…
Sponsor: Pamukkale University • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Wart war: two injections face off in plantar wart study
Disease control OngoingThis study tests two injected medications, bleomycin and pingyangmycin, for treating plantar warts. Each of the 200 adult participants will receive both drugs on different warts to compare which works better. The main goal is complete clearing of the warts, with follow-up for 36 …
Phase 4 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New antibody drug aims to calm painful skin condition
Disease control OngoingThis Phase 2 trial tests tibulizumab, a dual-action antibody, in 225 adults with hidradenitis suppurativa (HS), a chronic skin condition causing painful abscesses. Participants first receive either the drug or a placebo for 16 weeks, then everyone gets the drug for another 16 wee…
Phase 2 • Sponsor: Zura Bio Inc • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HS sufferers: Long-Term drug trial expands
Disease control By invitation onlyThis study looks at the long-term safety and effectiveness of a drug called sonelokimab for people with moderate to severe hidradenitis suppurativa (HS), a painful skin condition. About 835 adults and teens who completed an earlier sonelokimab study will receive the drug for an e…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Viruses vs. superbugs: new hope for skin infections?
Disease control By invitation onlyThis study tests a mixture of viruses called phages, which naturally kill bacteria, for treating skin infections that don't respond to antibiotics. Researchers will enroll 150 adults with infected wounds and compare the phage treatment to a placebo or standard care. The goal is t…
Early phase 1 • Sponsor: First Affiliated Hospital Xi'an Jiaotong University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
At-Home light therapy could zap nail fungus
Disease control OngoingThis study tests a new home-use LED light device to treat nail fungus (onychomycosis). Researchers want to find the best light dose and how often to use it. Fifty adults with nail fungus will use the device at home and be monitored for improvement.
Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug trial aims to help teens with painful skin condition
Disease control OngoingThis study tests a drug called sonelokimab in 35 teenagers aged 12 to 17 with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition that causes painful lumps. The main goals are to see how the drug moves through the body and whether it is safe. Researchers wi…
Phase 3 • Sponsor: MoonLake Immunotherapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could shorter antibiotic courses be better for hospitalized kids?
Disease control By invitation onlyThis study aims to find out if 5 days of antibiotics works as well as 10 days for children hospitalized with pneumonia, skin infections, or urinary tract infections. About 1,200 children will be randomly assigned to either a 5-day or 10-day course, with some receiving a placebo a…
Phase 4 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Engineered immune cells plus chickenpox vaccine take on childhood cancers
Disease control OngoingThis early-phase study tests a new treatment for advanced osteosarcoma and neuroblastoma that has not responded to standard therapy. Researchers take a patient's own immune cells (T cells), add a gene to help them recognize and attack cancer cells, and combine them with a chicken…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Shingles vaccine trial for transplant recipients: a safety check
Disease control By invitation onlyThis study looks at whether the shingles vaccine is safe and works well in young adults (19 and older) who have had a solid organ transplant. About 80 participants will get two doses of the vaccine and be monitored for side effects and immune response. The goal is to help protect…
Phase 4 • Sponsor: Ann & Robert H Lurie Children's Hospital of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New stitch technique aims to stop rare lung complication
Disease control By invitation onlyThis study tests if an extra stitch between the ribs during lung surgery can prevent a rare complication called lung hernia, where lung tissue bulges through the chest wall. About 104 adults having lung surgery will be split into two groups: one gets the extra stitch, the other g…
Sponsor: Mingjian Ge • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New topical drug could tackle stubborn toenail fungus
Disease control OngoingThis study tests a topical solution called Trichostatin A for mild-to-severe toenail fungus (onychomycosis). About 50 adults with a confirmed fungal infection will apply the drug daily for 4 weeks. Researchers will check safety and whether the fungus clears up using lab tests.
Phase 2 • Sponsor: Vanda Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Shingles shot put to the test in older HIV patients
Disease control OngoingThis study looks at how well the Shingrix vaccine protects against shingles in people over 50 living with HIV, compared to healthy adults of the same age and gender. About 225 participants will receive two doses of the vaccine and be monitored for one year. The goal is to see if …
Phase 4 • Sponsor: Calmy Alexandra • Aim: Disease control
Last updated Jun 26, 2026 13:35 UTC
-
Could women test for yeast infections at home? a swab test takes on the lab
Diagnosis OngoingResearchers are comparing the SavvyCheck Vaginal Yeast Test, a rapid swab test women use themselves, against standard vaginal yeast culture done in a lab. The study enrolls women with symptoms such as vaginal itching, discharge, soreness, or burning. The goal is to measure how ac…
Sponsor: Uniformed Services University of the Health Sciences • Aim: Diagnosis
Last updated Sep 12, 2026 00:00 UTC
-
Shingles vaccine trial aims to protect vulnerable patients
Prevention OngoingThis study tests the Shingrix vaccine in over 2,000 adults with autoimmune rheumatic diseases like rheumatoid arthritis and lupus, who are at higher risk for shingles. Researchers will compare vaccinated patients to unvaccinated ones to see if the vaccine is safe and triggers a s…
Phase 4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:29 UTC
-
Can adding a simple skin snip boost cellulite treatment?
Symptom relief OngoingThis study tests whether freezing fat cells (cryolipolysis) works better for cellulite when combined with a minor procedure that cuts the fibrous bands pulling down the skin (subcision). Fifteen healthy women with moderate to severe cellulite on both outer thighs will receive one…
Sponsor: Northwestern University • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Wrestlers try Beta-Alanine to boost performance and fight fatigue
Symptom relief OngoingThis study looks at whether taking beta-alanine, a common supplement, can help wrestlers perform better and feel less muscle fatigue during two days of simulated matches. Sixteen healthy wrestlers aged 12 to 25 will take the supplement and then do wrestling drills to measure thei…
Sponsor: China Medical University Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 13:06 UTC
-
New thrush treatment shows promise in early trial
Symptom relief OngoingThis study tests a product called pHyph for treating thrush (a vaginal yeast infection) in adult women. The goal is to see if pHyph reduces symptoms like itching, burning, and irritation. 48 women will either use pHyph daily for 6 days or receive no treatment, and researchers wil…
Sponsor: Gedea Biotech AB • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Could a different anesthesia method help diabetics during surgery?
Symptom relief OngoingThis study compares total intravenous anesthesia (TIVA) to balanced anesthesia (using inhaled gas) in 60 diabetic patients undergoing video-assisted chest surgery. The goal is to see which method better controls blood sugar and reduces stress during surgery. Researchers will also…
Phase 4 • Sponsor: Ain Shams University • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Shingles pain breakthrough? injections may beat standard drugs
Symptom relief OngoingThis study tests whether injecting a mix of lidocaine and steroids into tender points can better relieve shingles pain compared to standard painkillers alone. The trial involves 136 adults with severe shingles pain for less than 90 days. Researchers will track pain levels for up …
Sponsor: Beijing Tiantan Hospital • Aim: Symptom relief
Last updated Jun 26, 2026 13:48 UTC
-
Coffee warning for nail fungus patients?
Knowledge-focused By invitation onlyThis study checks if drinking caffeine changes blood pressure or heart rate in people taking the antifungal medication terbinafine for nail fungus. Researchers will monitor 52 adults before and after they start the drug. The goal is to understand possible side effects, not to tes…
Sponsor: Weill Medical College of Cornell University • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Can we finally outsmart recurrent yeast infections? a new study investigates
Knowledge-focused OngoingThis study aims to understand why some women get recurrent vaginal yeast infections (vulvovaginal candidiasis) and others don't. Researchers will compare the vaginal microbiome, immune markers, and metabolic profiles of women with and without the infection. By identifying key dif…
Sponsor: University Hospital, Antwerp • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Can a vaccine shield transplant patients from shingles?
Knowledge-focused OngoingThis study looks at how the immune system of kidney transplant patients responds to the shingles vaccine and to natural shingles infection. Researchers will track antibody and T-cell levels over time in patients who have had a transplant or are on the waiting list. The goal is to…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can immune cells predict herpesvirus danger in transplant patients?
Knowledge-focused OngoingThis study looks at how the immune system's T cells respond to two common herpesviruses—cytomegalovirus (CMV) and varicella-zoster virus (VZV)—in people who have had a liver transplant. Because transplant recipients take drugs that suppress their immune system to prevent organ re…
Sponsor: Susanne Dam Nielsen, MD, DMSc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Mystery infections in healthy people: scientists investigate
Knowledge-focused OngoingThis study looks at HIV-negative people who get opportunistic infections—illnesses that usually only affect those with weak immune systems. Researchers want to find out if these patients have unusual antibodies that block a key immune signal. Up to 224 adults in Thailand and Taiw…
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Do vaccines still work during lymphoma treatment? new study aims to find out
Knowledge-focused OngoingThis study tracks 56 follicular lymphoma patients to see how long their COVID-19 and other vaccine immunity lasts while they receive chemotherapy and maintenance therapy. Researchers will collect blood samples at several time points to measure immune responses. The goal is to und…
Sponsor: Fondazione Italiana Linfomi - ETS • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Shingrix vaccine study probes skin immunity in young and old
Knowledge-focused OngoingThis study looks at how the Shingrix vaccine, which protects against shingles, affects immune cells in the skin and blood. Researchers will give the vaccine to 50 healthy adults in two age groups: 30-40 years old and 70 years or older. They will measure specific antibodies and T-…
Phase 4 • Sponsor: University of Washington • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Scientists dig into the vaginal microbiome to unlock secrets of recurrent yeast infections
Knowledge-focused OngoingThis study looks at 120 Canadian women to understand why some get repeated yeast infections while others don't. Researchers will compare the vaginal yeast and bacteria of women with their first infection, those with recurrent infections, and those with yeast but no symptoms. Part…
Early phase 1 • Sponsor: University of Manitoba • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New study aims to find safe scabies treatment for toddlers
Knowledge-focused OngoingThis study looks at how well a single dose of ivermectin works in children under 5 with scabies. Researchers want to make sure the dose is safe and effective for this age group. About 120 children in Laos will take part, and the study will measure drug levels in the blood.
Phase 2 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Could a Baby-Friendly ivermectin formula beat scabies?
Knowledge-focused PausedThis trial compares a new ivermectin powder mixed with infant formula to the standard tablet in 52 healthy adults. The goal is to see if the new formulation is absorbed similarly, tastes better, and causes no new side effects. Results will guide future use in children with scabie…
Phase 1 • Sponsor: Murdoch Childrens Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New hospital program aims to cut unnecessary antibiotics for kids
Knowledge-focused OngoingThis study tests a 'discharge stewardship bundle' to help doctors prescribe the right antibiotics for the right duration when children leave the hospital. Over 1,100 children with pneumonia, urinary tract infections, or skin infections will be followed. Doctors receive feedback r…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC
-
Shingles vaccine safety in pregnancy under review for immunocompromised women
Knowledge-focused OngoingThis study looks at whether the shingles vaccine (HZ/su) is safe for pregnant women aged 18-49 with weakened immune systems. Researchers will track about 2,800 women to see if the vaccine raises the risk of birth defects or other problems in their babies. The goal is to provide r…
Sponsor: GlaxoSmithKline • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Beach danger? new study tracks illness from toxic algae
Knowledge-focused OngoingThis study follows 2,500 people who visit freshwater beaches in Ontario, Manitoba, and Nova Scotia to see if contact with water containing blue-green algae (cyanobacteria) leads to stomach bugs, respiratory issues, or skin/eye infections. Researchers will also track illness in pe…
Sponsor: Toronto Metropolitan University • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:54 UTC